⌘K
Loading ticker…
Arcutis Biotherapeutics, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Arcutis Biotherapeutics, Inc. Common Stock (ARQT) has a 3-month relative strength percentile of 72 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 60. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 4.6%, relative volume 2.06×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 72, Market Stance is mixed at 47, A/D rating B
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
ARQT is in a stage 3 topping pattern, week 11. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 17.4% / 11.4%.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
ARQT is held by 6 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $83M notional. Top 3 carry $227M.
Top 6 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $83M |
| XBIState Street SPDR S&P Biotech ETF | 1.09% | $81M |
| IWMiShares Russell 2000 ETF | 0.09% | $63M |
| VXFVanguard Extended Market ETF | 0.04% | $29M |
| IWOiShares Russell 2000 Growth ETF | 0.17% | $21M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $3M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARQT Jan avg: 19.03% median: 3.50% win: 50% σ: 43.05% n: 4 2022-04-12 → 2026-05-29 | ARQT Feb avg: 20.62% median: 4.85% win: 75% σ: 36.52% n: 4 2022-04-12 → 2026-05-29 | ARQT Mar avg: -8.50% median: -8.12% win: 25% σ: 19.25% n: 4 2022-04-12 → 2026-05-29 | ARQT Apr avg: 0.17% median: -2.84% win: 20% σ: 15.46% n: 5 2022-04-12 → 2026-05-29 | ARQT May avg: -12.39% median: -7.58% win: 40% σ: 19.69% n: 5 2022-04-12 → 2026-05-29 | ARQT Jun avg: 11.93% median: 9.38% win: 100% σ: 10.67% n: 4 2022-04-12 → 2026-05-29 (current) | ARQT Jul avg: 10.15% median: 11.06% win: 100% σ: 4.96% n: 4 2022-04-12 → 2026-05-29 | ARQT Aug avg: 0.96% median: 7.25% win: 75% σ: 15.25% n: 4 2022-04-12 → 2026-05-29 | ARQT Sep avg: -14.99% median: -21.81% win: 25% σ: 26.13% n: 4 2022-04-12 → 2026-05-29 | ARQT Oct avg: -10.37% median: -9.06% win: 25% σ: 37.57% n: 4 2022-04-12 → 2026-05-29 | ARQT Nov avg: 14.31% median: 9.28% win: 50% σ: 32.68% n: 4 2022-04-12 → 2026-05-29 | ARQT Dec avg: 15.75% median: 0.79% win: 50% σ: 40.77% n: 4 2022-04-12 → 2026-05-29 |